This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU) (PVAIN)

This study has been completed.
Genentech, Inc.
Information provided by (Responsible Party):
Melissa Scala, Georgetown University Identifier:
First received: March 29, 2011
Last updated: May 18, 2017
Last verified: May 2017
To evaluate the effect of Dornase alfa on preterm and late preterm neonates with ventilator associated pulmonary infections. Dornase alfa has been effective in the treatment of pulmonary infections in patients with cystic fibrosis by aiding mucus clearance. The bacteria causing pulmonary infections in cystic fibrosis patients is similar to those infecting preterm infants. The investigators expect that dornase alfa therapy will improve recovery from ventilator associated pulmonary infections in preterm infants.

Condition Intervention Phase
Pulmonary Infections Drug: Dornase alfa Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit

Resource links provided by NLM:

Further study details as provided by Melissa Scala, Georgetown University:

Primary Outcome Measures:
  • Percent Reduction in Oxygen Requirement From Baseline [ Time Frame: First week of treatment or extubation ]
    Change in required supplemental oxygen from baseline or time to extubation from mechanical ventilation

Secondary Outcome Measures:
  • Reduction in White Blood Cell Count and Bacterial Load From Tracheal Aspirate [ Time Frame: During first week of treatment or until extubation whichever is earlier ]
  • Number of Days on Ventilator Support [ Time Frame: 7 days ]

Enrollment: 11
Study Start Date: May 2011
Study Completion Date: April 30, 2017
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Sham placebo
No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
Drug: Placebo
No therapy will be given to placebo arm
Other Name: Sham therapy
Active Comparator: Dornase alfa
Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Drug: Dornase alfa
2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Other Name: Pulmozyme


Ages Eligible for Study:   up to 4 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • infants less than 38 weeks gestation and over 7 days of age
  • infants with a ventilator associated pulmonary infection, defined as intubated infants who have moderate to heavy White Blood Cells (WBCs) on tracheal aspirate, organisms on tracheal aspirate gram stain, a positive endotracheal tube culture, a chest x-ray with infiltrate, consolidation or atelectasis, an increase in oxygen (FiO2) requirement and whom the clinical team decides to treat with systemic antibiotic therapy

Exclusion Criteria:

  • Extremely ill infants not expected to survive
  • Critically ill infants requiring high frequency ventilation
  • Infants with congenital pneumonia
  • Infants with congenital malformations of the respiratory system (e.g. Congenital diaphragmatic hernia, cystic adenomatoid malformation or tracheo-esophageal fistula) Cyanotic congenital heart disease, chromosomal abnormalities and infants with a positive newborn screen for cystic fibrosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01356147

United States, District of Columbia
Georgetown University Hospital NICU
Washington, D.C., District of Columbia, United States, 20007
Georgetown University Hospital
Washington, D.C., District of Columbia, United States, 20007
Sponsors and Collaborators
Georgetown University
Genentech, Inc.
  More Information

Responsible Party: Melissa Scala, Assistant Professor of Pediatrics, Department of Neonatology, Georgetown University Identifier: NCT01356147     History of Changes
Other Study ID Numbers: Z4962s
Study First Received: March 29, 2011
Results First Received: December 15, 2016
Last Updated: May 18, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Melissa Scala, Georgetown University:
ventilator associated pulmonary infections

Additional relevant MeSH terms:
Communicable Diseases processed this record on August 16, 2017